Activmed Practices & Research, Inc

Portsmouth, New Hampshire 03801

0 studies enrolling now · 15 studies all time

What they study most

Actinic Keratosis, Alzheimer's Disease, Atopic Dermatitis, Binge-Eating Disorder, Chronic Pain, Hidradenitis Suppurativa, Hyperlipidemia, Low Back Pain, Osteoarthritis, Hip, Osteoarthritis, Knee, Plaque Psoriasis, Pneumococcal Disease

Studies at this site

• A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa — Running, not enrolling
• A Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis — Stopped early
• A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205 — Stopped early
• TRuE AD2 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis — Completed
• Multicenter Study to Evaluate the Efficacy and Safety of Oral ACT-539313 in the Treatment of Adults With Moderate to Severe Binge Eating Disorder — Completed
• Trial to Evaluate the Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-naïve Adults — Completed
• Safety and Efficacy Study of ALZT-OP1 in Subjects With Evidence of Early Alzheimer's Disease — Completed
• A Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis — Completed
• A Study of LY3375880 in Adults With Moderate-to-Severe Atopic Dermatitis — Stopped early
• A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on Actinic Keratosis on Face or Scalp (AK004) — Completed
• A Study of Ixekizumab (LY2439821) Compared to Guselkumab in Participants With Moderate-to-Severe Plaque Psoriasis — Completed
• A Phase 3 Study of Tanezumab for Chronic Low Back Pain — Completed
• Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee — Completed
• A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease — Stopped early
• Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular Events — Completed